Pharmaceuticals & Therapeutics

Altruist Biologics secures a landmark license for China's largest bioreactor facility, signaling a major shift in the global biopharmaceutical supply chain.

With a $137M war chest, Sidewinder Therapeutics is advancing a new class of ultra-precise cancer drugs aimed at tumors that have long evaded treatment.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

The dermatologist-founded brand is expanding access to clinical-grade treatments for underserved skin concerns, signaling a major shift in the industry.

Hemispherian launches a landmark trial for GLIX1, a first-in-class therapy aiming to selectively destroy glioblastoma cells where others have failed.

A new alliance between Daiichi Sankyo and ATLATL aims to leverage a unique 'Super Server' model to fast-track novel therapies from Asia to the world.

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?

A strategic partnership with 5 Horizons Ventures accelerates Marvel Biosciences' novel drug, MB-204, into human trials for autism, Rett syndrome, and more.

Early Phase 3 results show gotistobart dramatically extends survival for lung cancer patients with limited options, heralding a potential new standard of care.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

A new partnership brings a groundbreaking protocol for corneal blindness to Chicago, expanding a national network dedicated to restoring vision for thousands.

As employers face staggering GLP-1 expenses, a new program aims to deliver measurable outcomes by integrating clinical support directly into pharmacy benefits.

Eosera just unveiled its largest product launch ever, aiming to become the authority in a growing OTC market with new solutions for pain, itch, and wellness.

A new poll shows two-thirds of workers are more likely to use GLP-1s with employer coverage, highlighting the role of cost, support, and stigma.

Life Sciences Ontario's new board appointments signal a strategic shift, bringing in leaders from medtech, agri-tech, pharma, and nuclear isotopes.

Royal Biologics' new Fibrinet system uses a patient's own blood to create a living bandage, a major step forward for treating diabetic and venous ulcers.

Backed by a $41.3M ARPA-H award, SonoNeu is pioneering sonogenetics, a non-invasive therapy using ultrasound to control cells and treat nerve pain.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.